AstraZeneca shares drop by 6% after halting COVID-19 vaccine trials
Category: #headlines  By Nikita Chaurasia  Date: 2020-09-10
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca shares drop by 6% after halting COVID-19 vaccine trials

AstraZeneca plc, a British-Swedish pharmaceutical & biopharmaceutical leader, has recently made it to the headlines for witnessing a 6% plunge in shares after voluntarily halting its late-stage trial for a potential COVID-19 vaccine.

Sources close to the matter cited that the company had put the trial on hold as mean of caution after a study participant in the United Kingdom was experiencing adverse reactions of the potential vaccine.

For the uninitiated, AstraZeneca had developed a vaccine called AZD1222 which was engineered to use a modified adenovirus that carries certain genetic materials of the coronavirus.

The vaccine uses the technology that was employed for developing an experimental Ebola vaccine that was catered to people in the Democratic Republic of Congo in the year 2019, sources claimed.

It is to be noted that the U.S. government struck a deal with AstraZeneca and funded over USD 1.2 billion for the development of a COVID-19 vaccine as well as to secure at least 300 doses for the U.S. population.

Researchers involved in the trials claimed that the AZD1222 vaccine showed no adverse effects apart from headache, fatigues, muscle pain, and fever. The nature of the case leading to the suspension of the trials is not known, however, the volunteer is expected to recover soon.

Evidently, AstraZeneca had commenced the trial round towards the end of last month and is one of three companies to initiate late-stage testing for a potential vaccine. The other two companies are Massachusetts-based biotech company Moderna and Pfizer Inc., a renowned pharmaceutical corporation.

In other news, the Russian Health Ministry has reportedly initiated the distribution of the first batch of the COVID-19 vaccine Sputnik V, which is developed by Gamaleya National Research Center of Epidemiology & Microbiology.

Source credits: https://www.cnbc.com/2020/09/08/astrazeneca-shares-fall-after-coronavirus-vaccine-study-is-put-on-hold.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

U.K.’s competition regulator might look into the music streaming space

U.K.’s competition regulator might look into the music streaming space

By Nikita Chaurasia

The Competition and Markets Authority of the U.K. has revealed plans to launch a probe targeting the country’s music streaming market to ascertain if it is sufficiently consumer-centric and competitive. The announcement came after a U.K. parli...

India’s vaccination drive slows down as dose gap holds back output

India’s vaccination drive slows down as dose gap holds back output

By Nikita Chaurasia

India’s vaccination efforts have reportedly slowed down despite stockpiling vaccines as authorities are maintaining a more than usual gap between two shots. This is a part of the strategy to boost vaccine coverage in the country. The domestic ...

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

McDonald’s to test McPlant meatless burger at eight U.S. restaurants

By Nikita Chaurasia

The McPlant patty is developed in collaboration with Beyond Meat Inc. It will be prepared using vegetarian ingredients like peas, potatoes, and rice. McDonald’s will reportedly start offering its first vegetarian option in the U.S., the ne...